Format

Send to

Choose Destination
Eur Thyroid J. 2018 Oct;7(5):238-242. doi: 10.1159/000493123. Epub 2018 Sep 28.

European Thyroid Association (ETA) and Thyroid Federation International (TFI) Joint Position Statement on the Interchangeability of Levothyroxine Products in EU Countries.

Author information

1
Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands.
2
Evolution des Régulations Endocriniennes, Département "Adaptation du Vivant", UMR 7221 Muséum National d'Histoire Naturelle/CNRS, Paris, France.
3
Montreal, Québec, Canada.
4
Department of Endocrinology and Metabolism, Odense University Hospital, Odense C, Denmark.

Abstract

Several European countries have seen major health issues after a switch from one levothyroxine brand to another, as well as following the introduction of several levothyroxine formulation changes. While the relationship between these health issues and brand or formulation changes merits further investigation, the current position statement on behalf of both health-care providers and patients summarizes recent events in several European countries and provides a number of recommendations to limit the burden for patients, so as to prevent increased health-care consumption and health-care expenses in this context.

KEYWORDS:

European Thyroid Association; Health issues; Levothyroxine products; Thyroid Federation International

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
Loading ...
Support Center